PubAg

Main content area

Efficacy of Fostera® PRRS modified live virus (MLV) vaccination strategy against a Thai highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) infection

Author:
Charoenchanikran, Ponlakrit, Kedkovid, Roongtham, Sirisereewan, Chaitawat, Woonwong, Yonlayong, Arunorat, Jirapat, Sitthichareonchai, Panchan, Sopipan, Natthawan, Jittimanee, Suphattra, Kesdangsakonwut, Sawang, Thanawongnuwech, Roongroje
Source:
Tropical animal health and production 2016 v.48 no.7 pp. 1351-1359
ISSN:
0049-4747
Subject:
Porcine reproductive and respiratory syndrome virus, blood serum, farms, herds, industry, lungs, morbidity, piglets, porcine reproductive and respiratory syndrome, respiratory tract diseases, survival rate, temperature, vaccination, vaccines, viral load, viruses, weaning
Abstract:
Recently, the Chinese highly pathogenic porcine reproductive and respiratory syndrome virus (PRRSV) (HP-PRRSV) belonging to lineage 8 causes severe symptom with high morbidity and high mortality rates to the Asian pig industry. A recent study showed that pigs immunized with Fostera® PRRS modified live virus (MLV) of lineage 8 could provide a degree of protection against a Vietnamese HP-PRRSV infection. It should be noted that PRRSV commonly found after weaning causes porcine respiratory disease complex (PRDC). Vaccination strategy should be evaluated in each farm scenario. Eighty-one PRRSV-free piglets obtained from a PRRS-free herd were divided into two experiments with the major difference of infection timing after vaccination, 42 days in experiment 1 (n = 42) and 28 days in experiment 2 (n = 39). Each experiment had similar protocol containing three groups including a negative control, unvaccinated challenged, and vaccinated challenged groups. Pigs in vaccination groups were immunized with Fostera® PRRS MLV vaccine at 3 weeks of age. Then, unvaccinated challenged and vaccinated challenged groups were intranasally inoculated with a Thai HP-PRRSV (10PL01). Vaccinated challenged pigs showed significantly lower levels of mean rectal temperatures, clinical severity, lung lesion scores, and viral titers in serum and lung tissue compared to the unvaccinated challenged pigs (p < 0.05). Vaccinated challenged pigs had higher survival rate than those of unvaccinated challenged pigs in both experiments. It should be noted that pigs challenged 42 days after vaccination showed a better performance than pigs challenged 28 days after vaccination. In conclusion, Fostera® PRRS MLV vaccine was able to improve the survival rate against the Thai HP-PRRSV infection in both 42- and 28-day vaccination-to-infection protocols.
Agid:
5558142